New kidney drug trial aims to find safe doses for patients
NCT ID NCT07445906
First seen Mar 05, 2026 · Last updated Jun 21, 2026 · Updated 19 times
Summary
This early-stage study tests a single injection of RG002C0106 in 24 adults to see how kidney function affects the drug's levels and safety. Participants have either normal kidneys or mild-to-moderate kidney impairment. The goal is to gather basic information, not to treat the disease.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for IGA NEPHROPATHY (IGAN) are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Email: •••••@•••••
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
RG002C0106 injection
What this could lead to
If successful, this study could help determine safe dosing of RG002C0106 for people with kidney problems, potentially guiding future trials.
What could go wrong
This is a very early Phase I trial with only 24 participants, so results may not apply broadly. The drug's safety and effectiveness are still unknown.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.